Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
Completed
- Conditions
- GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
- Registration Number
- NCT01303692
- Lead Sponsor
- AstraZeneca
- Brief Summary
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
- Detailed Description
MC MD
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 312
Inclusion Criteria
- Korean prostate cancer over 50 years old with pathological confirmation
- Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting.
- Patients measured bone density level before starting to receive hormone therapies above.
Exclusion Criteria
- Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0.
- Patients who are hard to be analysed by attach to other bone disease.
- Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method comparison of bone density between GnRH agonist alone vs. CAB group 1 year comparison of bone density before and after hormone therapy 1 year
- Secondary Outcome Measures
Name Time Method 1year comparison of FRAX score before and after hormonal therapy 1 year correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value 1 year correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value before and after hormone therapy 1 year
Trial Locations
- Locations (1)
Research Site
🇰🇷Seoul, Korea, Republic of